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Background: Drugs targeting insomnia ideally promote sleep throughout the night, maintain normal sleep
architecture, and are devoid of residual effects associated with morning sedation. These features of an ideal
compound are not only dependent upon pharmacokinetics, receptor binding kinetics, potency and
pharmacodynamic activity, but also upon a compound’s mechanism of action.
Results: Dual orexin receptor antagonists (DORAs) block the arousal-promoting activity of orexin peptides and, as
demonstrated in the current work, exhibit an efficacy signal window dependent upon oscillating levels of
endogenous orexin neuropeptide. Sleep efficacy of structurally diverse DORAs in rat and dog was achieved at
plasma exposures corresponding to orexin 2 receptor (OX2R) occupancies in the range of 65 to 80%. In rats, the
time course of OX2R occupancy was dependent upon receptor binding kinetics and was tightly correlated with the
timing of active wake reduction. In rhesus monkeys, direct comparison of DORA-22 with GABA-A modulators at
similar sleep-inducing doses revealed that diazepam produced next-day residual sleep and both diazepam and
eszopiclone induced next-day cognitive deficits. In stark contrast, DORA-22 did not produce residual effects.
Furthermore, DORA-22 evoked only minimal changes in quantitative electroencephalogram (qEEG) activity during
the normal resting phase in contrast to GABA-A modulators which induced substantial qEEG changes.
Conclusion: The higher levels of receptor occupancy necessary for DORA efficacy require a plasma concentration
profile sufficient to maintain sleep for the duration of the resting period. DORAs, with a half-life exceeding 8 h in
humans, are expected to fulfill this requirement as exposures drop to sub-threshold receptor occupancy levels prior
to the wake period, potentially avoiding next-day residual effects at therapeutic doses.
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As a primary arousal signal in wake control, orexin signal-
ing is necessary for normal circadian regulation of con-
solidated wakefulness; exogenous application of orexin
neuropeptides or optogenetic activation of orexin neurons
induce arousal and genetic loss of orexin signaling is as-
sociated with narcoleptic symptoms [1,2]. Endogenous* Correspondence: john_renger@merck.com
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reproduction in any medium, provided the ororexin peptide levels oscillate over the course of the day:
secretion during waking hours induces a peak in orexin
levels late in the active phase, and rapidly decreasing activ-
ity precedes a nadir in levels during the inactive phase
[3,4]. Orexin-A (OX-A) and -B (OX-B) are processed pep-
tide products of the HCRT (hypocretin) gene, which en-
codes the prepro-orexin peptide [5]. OX-A has similar
affinity for both orexin-1 and -2 receptors (OX1R and
OX2R, respectively), while OX-B selectively favors OX2R
binding [6]. Exogenous administration of OX-A is most ef-
fective in promoting wakefulness when applied duringLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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normally low [7-9]. Conversely, blocking orexin activity
with dual orexin receptor antagonists (DORAs) is most
easily measured during the active phase [10-12].
Therapy targeting insomnia requires defined pharma-
codynamic timing. Unlike most other central nervous
system therapeutics, compounds utilized in the thera-
peutic treatment of insomnia will, ideally, promote sleep
throughout the resting period, maintain normal sleep
architecture, and avoid residual effects upon waking,
thus allowing for full wakefulness during the subsequent
active period. This time-limited efficacy requires phar-
macokinetic exposure and sufficient central receptor
occupancy levels to drive sleep efficacy when desired,
and reduced compound exposure to avoid residual
effects upon waking. This limitation of duration of activ-
ity makes the half-life (T1/2) of γ-aminobutyric acid
(GABA-A) receptor modulators a key defining feature of
their clinical utility. Next-day/carry-over effects, in par-
ticular, are well-documented undesirable mechanism-
related adverse effects of conventional therapies with
long half-lives [13,14]. The current standards of care,
benzodiazepine and non-benzodiazepine GABA-A re-
ceptor modulators, can also be associated with bother-
some morning sedation and cognitive residual effects. In
contrast, the current data on DORAs suggest that these
compounds induce physiological sleep and demonstrate
only mild residual effects despite relatively long plasma
T1/2 [10,12,15-18]. Preclinical studies of compounds with
balanced potency at OX1R and OX2R, such as DORA-
22, an analog of MK-6096 [2,18,19], demonstrate little or
no effect on electroencephalogram (EEG) spectral fre-
quency distribution, suggesting that blockade of orexin-
mediated wakefulness allows sleep to occur that is similar
to that measured in vehicle-treated controls [20].
Pharmacologically, the duration of sleep-promoting ef-
ficacy depends not only upon a compound’s mechanism
of action, but also upon its pharmacokinetics, receptor-
binding kinetics and potency, as these properties dictate
the timing of receptor occupancy required for in vivo ef-
fects important for a compound’s overall activity and
clinical utility. Clearly, rapid central nervous system
penetration is essential for sleep-onset efficacy, and a
moderate pharmacokinetic T1/2 and sufficiently high re-
ceptor occupancies are required for sleep maintenance
throughout the desired resting period. However, to avoid
next-day residual effects, compound levels must drop
below exposures required for minimum effective recep-
tor occupancy by the onset of wakefulness to avoid re-
sidual sleep effects. In principle, compounds that are
effective at a low receptor occupancies are challenged to
restrict sleep promoting effects to the resting phase,
compared to mechanisms that require a higher occu-
pancy threshold that are less likely to exhibit carry-overeffects for a given pharmacokinetic profile and T1/2. Here,
we characterize the pharmacokinetic and receptor occu-
pancy properties underlying the timing of efficacy elicited
by structurally distinct DORAs including DORA-12 and
DORA-22, close analogs of suvorexant and MK-6096
whose chemical properties have been described previously
[19,21,22]. The ensemble of pharmacokinetic, receptor-
binding kinetics and pharmacodynamic properties of
DORAs appear advantageous to restricting the wake-
inhibition efficacy of these compounds to the resting phase.
Results
OX-A levels are associated with wakefulness
across species
To more precisely define the timing of changes in orexin
levels, their relationship with arousal and therefore the
available signal window for the DORAs over the course
of the circadian day, OX-A levels in cerebrospinal fluid
(CSF) were determined by meso-scale immunoassay and
correlated with baseline active wake as measured by
polysomnography (PSG) in nocturnal and diurnal pre-
clinical species. In nocturnal mice and rats, OX-A levels
progressively drop during the inactive period, reaching a
nadir in the second half of this period, and accumulate
over the course of the dark (active) period (Figure 1A).
Mean time in active wake generally mimics these OX-A
levels. In diurnal dogs and rhesus monkeys, OX-A levels
build during the light (active) period and fall during the
resting period, coincident with increased arousal during
the day and decreased wakefulness at night (Figure 1B).
These observations predict that DORAs will have max-
imum efficacy in the late dark phase of nocturnal species
and the late light phase of diurnal animals which corre-
lates to the active periods of both types of species.
DORA efficacy in rats is most salient during the
active phase
The sleep-promoting effects of DORAs were greatest
during the active phase when orexin levels were highest
in normal rats entrained to a 12:12 light:dark cycle.
When administered during the mid-active phase, DORA-
22 (30 mg/kg), an MK-6096 analog structurally distinct
from suvorexant and DORA-12, promoted sleep charac-
teristic of a DORA: active wake was attenuated for up
to 8 h, and both delta and REM sleep were increased
for up to 6 h following treatment (Figure 2A). The
magnitude of wake-reducing activity was diminished
when normal rats were administered DORA-12 just
prior to the inactive phase onset and was accompanied
by small variable increases in delta and rapid eye move-
ment (REM) sleep (Figure 2B). Importantly, changes in-
duced by DORA-22 administered just prior to the
inactive phase trend in the same direction as that seen
in vehicle-treated animals progressing from the active
Zeitgeber TimeZeitgeber Time
Figure 1 Active wake closely follows oscillating OX-A levels across preclinical species. The time course of OX-A levels in CSF and active
wake were highest during the dark phase in nocturnal rodents (A) and during the light phase in diurnal species (B). Mean OX-A levels and time
spent in active wake are plotted ± standard error of the mean (SEM) over a 24-h period (dark period shaded) for 6-h and 30-min intervals,
respectively. OX-A levels were determined by meso-scale immunoassay at 6-h time points in mice (n = 3; 50 pooled CSF samples each), rats (n = 8
samples each), dogs (n = 8 samples each), and rhesus monkeys (n = 8 samples for ported animals, each). Mean time in active wake under baseline
conditions was determined by EEG from telemeterized mice (6 days, n = 7), rats (6 days, n = 7), dogs (10 days, n = 6), and rhesus monkeys
(5 days, n = 7).
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increased slow wave sleep (SWS), and small fluctua-
tions in REM sleep.
DORA-induced efficacy occurs at OX2R occupancies
exceeding 65%
A dose response for DORA-12, a structural analog of
suvorexant, was evaluated in rat PSG studies to deter-
mine the relationship between sleep-promoting efficacy
as measured by active wake reduction and OX2R occu-
pancy. Dose-dependent attenuation of active wake was
observed with DORA-12 (Figure 3A), which also re-
sulted in corresponding increases in non-REM and REM
sleep. Sleep-promoting efficacy induced by each dose of
DORA-12 was quantified as a percent change in active
wake relative to the vehicle-induced response over 2 h
following treatment.Separately, the relationship between OX2R occupancy
relative to plasma exposure was determined by adminis-
tering DORA-12 intravenously (i.v.) over a range of
doses to transgenic rats expressing human OX2R to de-
termine a full occupancy curve over a wide range of
plasma concentrations in order to define the maximal
occupancy against which raw occupancy values could be
normalized. This relationship was then used to deter-
mine the OX2R occupancy in PSG experiments from
measured plasma concentrations. The maximum plasma
concentration (Cmax) observed in satellite animals dosed
in parallel with those used in PSG experiments were
used for these analyses since Cmax occurs during the first
two hours after treatment. Increased OX2R occupancy,
achieved at higher doses, was accompanied by progres-
sively greater attenuation of active wake (Figure 3B).
This same pattern was also observed for suvorexant and
Figure 2 Sleep-promoting effects of DORA-22 in normal rats are diminished during the inactive phase. Vehicle (20% Vitamin E TPGS, p.o.)
and DORA-22 (30 mg/kg) were administered to rats during the mid-active phase (arrow, ZT 17:00; n = 13) (A) or 1 h before the inactive phase
(arrow, ZT 23:00; n = 8) (B) in a balanced cross-over design. Values represent mean time in sleep stage over 30-min intervals over 3 days of
consecutive treatment. Gray shading denotes the dark or active period. AW, active wake; QW, quiet wake. Time points at which significant
differences exist between vehicle and DORA-22 responses are indicated by gray vertical lines and tick marks (short, medium, long marks: P < 0.05,
0.01, 0.001, respectively).
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DORA-22. Generally, compound-induced attenuation of
active wake became salient and significant at OX2R oc-
cupancies between 63 and 83%. While 0.3 and 1 mg/kg
doses of DORA-12 marginally reduced active wake, this
change became highly significant at 3 mg/kg, where
plasma levels reached 0.20 μM, corresponding to 83%
OX2R occupancy (Figure 3, Table 1). For comparison, ef-
ficacy as determined by active wake reduction, plasma
exposure, and OX2R occupancy in rats are presented for
each dose of suvorexant and DORA-12 in Table 1.
It was previously shown that suvorexant attenuated ac-
tive wake in dogs in a dose-dependent manner with cor-
responding increases in non-REM and REM sleep: the
effects of 1 mg/kg on active wake were observed for up
to 4 h, and 3 mg/kg responses for up to 7.5 h [12]. Re-
examination of the time course of plasma exposures in-
dicated that suvorexant efficacy was observed at time
points when plasma concentrations were in excess of
0.342 μM (Figure 4A), a plasma exposure corresponding
to 65.7% OX2R occupancy calculated from rat occu-
pancy values normalized for both rat and dog unboundplasma values (1.4 and 1.0%, respectively). Time points
showing active wake reduction following administration
of suvorexant (1 and 3 mg/kg) coincided with plasma
exposures that were calculated to result in ≥65% OX2R
occupancy (Figure 4B), consistent with the range of ef-
fective occupancy observed in rats.
OX2R binding kinetics contribute to the timing of DORA
receptor occupancy
To determine the influence of OX2R binding kinetics
on receptor occupancy and sleep-promoting efficacy,
the time course of in vivo effects in response to
DORA-12 was compared with that of almorexant, a
compound known to exhibit exceedingly slow dissoci-
ation from OX2R. Almorexant is well documented to
have slow binding kinetics relative to other DORAs
[18,23]. Depending upon the method and competing
ligand used, the T1/2 of almorexant for association
with OX2R ranges from 28 to 162 min and from 70
to 268 min for dissociation (the later values obtained in
current experiments comparing 6 different DORAs
in Table 2). DORA-12 (30 mg/kg) and almorexant
Zeitgeber Time
Figure 3 Sleep efficacy of DORA-12 in rats is associated with
OX2R occupancies between 63 and 83%. A. Attenuation of mean
time in active wake in rats in response to DORA-12 (1 mg/kg [n =
14], 3 mg/kg [n = 14], 10 mg/kg [n = 8], and 30 mg/kg [n = 14)
relative to vehicle (20% Vitamin E TPGS, p.o.) dosed mid-active phase
(arrow). Gray shading, dark period. Time points at which significant
differences exist between vehicle and DORA-12 responses are
indicated by gray vertical lines and tick marks (short, medium, long
marks: P < 0.05, 0.01, 0.001, respectively). Maximum plasma values
(Cmax) and corresponding occupancy values determined in satellite
animals are listed to the right. B. The mean percent change (± SEM)
in active wake quantified from individual PSG recordings from ‘A’
versus percent OX2R occupancy determined in rats (satellite
animals). Light and dark shading indicates potential and definitive
occupancy ranges. *** P < 0.001 (t-test) difference in percent active
wake change versus baseline.
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phase and just prior to the inactive phase, a therapeutically
relevant dosing time, in rats. DORA-12 significantly attenu-
ated active wake for approximately 6 h following dosing
during the active phase and up to 3.5 h after treatment
at the inactive phase onset (P <0.05 through 0.001; see
Figure 5A, upper panels). Almorexant-dependent re-
ductions in active wake were seen for up to 7.5 h after
treatment during the active phase and for up to 11 h
following inactive-phase treatment (Figure 5B, upper
panels).
Plasma and CSF levels of DORA-12 and almorexant,
as well as OX2R occupancy were determined in satellite
rats following treatment at the onset of the inactive
phase. As seen in Figure 5A (lower panels), DORA-12
plasma and CSF levels began to fall immediately after
dosing, with corresponding decreases in OX2R occu-
pancy to 77% of maximum at 8 h, coincident with the
cessation of sleep-promoting effects. OX2R occupancy
by almorexant, however, remained elevated at 10 h, even
though levels within the CSF were undetectable at this
time point (Figure 5B, lower panels). The persistence of
OX2R occupancy by almorexant despite disappearing
levels of the compound in the plasma and CSF is con-
sistent with its extremely slow receptor-binding kinetics
relative to other DORAs including suvorexant, MK-
6096, DORA-22 and SB-649868 (Table 2). Together
these results indicate that binding kinetics have the cap-
acity to influence receptor occupancy and sleep promot-
ing efficacy, particularly for compounds with excessively
slow kinetic parameters.
Next-day sleep, qEEG, and quantitative effects in
rhesus monkeys
To evaluate the potential for both GABA-A receptor
modulators and DORA-22 to promote sleep through the
resting phase and into the subsequent active phase, rhe-
sus monkeys were administered these compounds 2 h
before lights out. The doses, diazepam at 10 mg/kg,
eszopiclone at 10 mg/kg, and DORA-22 at 30 mg/kg,
were selected based on their similar potential to pro-
mote sleep following active-phase dosing. Quantified
over 2 h, these treatments have previously been found to
attenuate active wake by 38.4, 55.0, and 40.1 min relative
to vehicle, respectively [24].
Diazepam, eszopiclone, and DORA-22 produced char-
acteristic plasma-exposure profiles (Figure 6A). The
anxiolytic diazepam exhibited a peak at 1.0 h (775 nM),
eszopiclone induced a more rapid Cmax at 0.5 h (1680
nM), and DORA-22 a more delayed exposure profile
(134 nM at 2 h). All three compounds significantly
attenuated active wake in the 2 h after dosing before
the onset of the inactive phase (Figure 6B). Unlike
eszopiclone and DORA-22, diazepam significantly attenu-
Table 1 Efficacy as measured by active wake reduction by suvorexant and DORA-12 relative to plasma exposure and
OX2R exposure in rats
Compound Dose (mg/kg) Plasma (nM) OX2R Occ
a (% maxb) Active wake reductionc %
Suvorexant 10 1600.0 92.6 -29.0***
30 2100.0 94.3 -79.6**
100 5100.0 97.6 -79.9**
DORA-12 0.3 20.2 34.0 -7.9
1 67.4 62.8 -9.7
3 202.2 83.0 -28.8***
10 674.0 93.9 -44.2***
30 2022.0 97.1 -45.9***
aOcc, occupancy.
bNormalized occupancy was determined over a range of doses and fit to a one-sided binding hyperbolic curve to determine the maximum occupancy. OX2R
occupancies corresponding to plasma values at indicated doses were calculated based on the normalized curve for each compound.
cMean percent change in active wake relative to vehicle in the 2 h following treatment (**, ***, p < 0.01, 0.001, population t-test).
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phase and 3 h into the subsequent active phase. Despite
the presence of measurable eszopiclone and DORA-22
plasma levels 17 h after treatment, no consistent attenu-
ation of active wake was observed in response to either
compound the morning after treatment.
Quantitative EEG analysis performed coincident with
PSG revealed time-dependent and qualitative differencesFigure 4 Suvorexant efficacy in dogs corresponds to plasma
exposures > 342 nM and OX2R occupancies > 65%. A. Suvorexant
levels in satellite animals treated with suvorexant (1 or 3 mg/kg; p.o.
in 20% Vitamin E TPGS) (n = 3, each time point). B. Calculated OX2R
occupancy based on rat occupancy values, and normalized for free
fraction of compound in rat (1.4%) and dog (1%). Gray shading
indicates time points at which active wake was significantly
attenuated in dogs treated with suvorexant (1 or 3 mg/kg), the
plasma and occupancy range at which efficacy has been
observed [12].between the effects of these compounds that were not
evident in measurements of active wake. All three com-
pounds increased delta frequency qEEG power in ad-
vance of the normal increase in delta power observed
during the resting phase after administration of vehicle
(Figure 6C, bottom panels). However, both diazepam
and eszopiclone increased high-frequency gamma power
and substantially decreased theta power throughout the
inactive period, while DORA-22 had essentially no effect
on these measures (Figure 6C, top and middle panels).
The effects of diazepam persisted into the subsequent
active period while eszopiclone-induced qEEG changes
ceased abruptly upon lights on (at which point cognitive
tests were performed). The relevance of compound-
induced qEEG changes occurring during cognitive test-
ing intervals is currently unknown.
In order to better understand the consequences of
compound-induced sleep and qEEG effects that persist
though the inactive period, cognitive memory and at-
tention parameters were evaluated in the same rhesus
monkeys, the morning after treatment. Memory was
evaluated in the delayed match to sample (DMS) task
performed at lights on (14 h after dosing), while atten-
tion was evaluated in the serial choice retention time
(SCRT) test administered 2 h later (16 h after dosing;
see Figure 6C, bottom panels, D and C time points).
Significant deficits in recognition memory, as assessed
by DMS, were observed the morning after treatment
with diazepam (10 mg/kg) but not following eszopiclone
(10 mg/kg) or DORA-22 (30 mg/kg) relative to their re-
spective vehicle treatments (Figure 6D). These results
are consistent with diazepam-dependent active wake at-
tenuation persisting into the active period. Despite the
presence of measurable levels of this DORA-22 three
hours after the DMS task was performed (Figure 6A; 61
nM), no attenuation of in performance was observed. In
SCRT, both diazepam and eszopiclone elicited significant
Table 2 Orexin 2 receptor binding kinetic parameters for DORAs
Compound Kd (nM) T1/2 ON (min) KON (mol
-1 · min-1) T1/2 OFF (min) KOFF (min
-1)
Almorexant 0.048 162a 1.58 × 107 268 2.696 × 10-3
Suvorexant 0.401 80.1 7.63 × 106 89.4 7.784 × 10-3
DORA-12 0.157 57.5 2.77 × 107 232 3.154 × 10-3
MK-6096 0.338 62.9 1.69 × 107 118 6.754 × 10-3
DORA-22 0.834 24.7 9.19 × 106 37.8 1.878 × 10-2
SB-649868 0.163 37.0 2.56 × 107 57.0 1.258 × 10-2
aAlmorexant T1/2 ON represents an underestimate as almorexant was applied at concentrations 3-fold above its Kd in order to measure its kinetics alongside
other DORAs.
Kd, binding constant; KOFF, dissociation constant; KON, association constant; T1/2 OFF, half-life off-rates; T1/2 ON, binding half-life.
Figure 5 Time course of DORA-12 and almorexant OX2R occupancy and efficacy in rats. A (upper panels). The time course of DORA-12
(30 mg/kg) effects on active wake was determined in rats by telemetry PSG relative to vehicle (20% Vitamin E TPGS, p.o.) following treatment in
active (n = 14) or inactive phase (n = 7). Time points at which significant differences exist between vehicle and DORA-12 responses are indicated
by gray vertical lines and tick marks (short, medium, long marks: P < 0.05, 0.01, 0.001, respectively). B (upper panels). Effects of almorexant
(100 mg/kg) on active wake relative to vehicle following treatment in active (n = 14) or inactive phase (n = 14). Lower panels. Plasma and CSF
levels as well as OX2R receptor occupancy of DORA-12 (A) and almorexant (B) following inactive phase treatment (one male, one female animal
per time point). Plasma, CSF, and occupancy levels were determined in the same animals, in satellite to PSG experiments.
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Figure 6 Diazepam and eszopiclone, but not DORA-22, exhibit next-day effects impacting cognitive performance in monkeys. Monkeys
were treated (arrow) with sleep-promoting doses 2 h before the 12-h dark/inactive phase (gray shading): diazepam, 10 mg/kg, p.o. in 0.5%
methylcellulose; eszopiclone, 10 mg/kg, in 20% Vitamin E TPGS; DORA-22, 30 mg/kg, in 20% Vitamin E TPGS. Memory and attention were
evaluated by DMS (D) and SCRT (C) tasks 14 and 16 h after dosing, respectively. A. Time course of plasma levels after dosing (0, 0.25, 0.5, 1, 2, 4,
6, 17 h; n = 2, diazepam and eszopiclone; n = 3, DORA-22 [17 h, n = 8]). Normalized plasma levels relative to maximum (Cmax: diazepam 775
nM [1 h]; eszopiclone 1680 nM [0.5 h]; DORA-22 134 nM [2 h]) compare compound levels on the same y-axis scale. B. Mean time in active
wake (+ SEM) determined by polysomnography in 30-min intervals after treatment (vehicle, closed symbols; compound, open symbols).
Significant differences versus vehicle are indicated by gray vertical lines and tick marks (short, medium, long: P < 0.05, 0.01, 0.001,
respectively). C. Mean qEEG power in gamma (35–100 Hz), theta (4–8 Hz), and delta (0.5–4 Hz) frequency bands following treatment.
D. DMS measure of memory at 14 h after treatment. Data are mean proportions of completed trials during which a correct choice was
made (+ SEM; n = 16, 16, and 15, respectively). Random responding, 25%. Significant differences from vehicle: * P < 0.05 (repeated measures
ANOVA). E. SCRT evaluation of attention at 16 h after treatment. Data are the mean proportions of completed trials during which a correct
choice was made following short duration cues (+ SEM; n = 16, 16, and 5, respectively). Random responding, 10%. Significant differences
from vehicle: * P < 0.05.
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the shortest duration relative to vehicle-treated controls
(P < 0.05 for both) (Figure 6E). In contrast, deficits in
next-day attention were not observed with DORA-22.Suvorexant exposure time course in humans
Plasma samples obtained in an Phase 1 clinical evalu-
ation of suvorexant exhibited a common exposure pro-
file, with a time to maximum plasma concentration
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levels of suvorexant sufficient for 65% OX2R occupancy
were calculated based on extensive transgenic rat occu-
pancy data and normalized for free fraction (rat: 1.4%;
human: 1.0%). The human plasma concentration of
suvorexant calculated to correspond to 65% OX2R occu-
pancy is 0.33 μM (free + bound). Observed clinical
suvorexant mean plasma concentrations fell below the
levels predicted to correspond to 65% OX2R occupancy,
where sleep-promoting efficacy is predicted, by the 8 h
post-dose time point for both the 10 and 20 mg thera-
peutic doses. Together this analysis indicates that the
sleep promoting effects of suvorexant would not be
expected to persist into subsequent waking hours at
therapeutic doses less than 20 mg.
Discussion
Timing of the pharmacodynamic efficacy of drugs
targeting insomnia is critical to promote sleep mainten-
ance throughout the resting phase and to avoid un-
desired next-day effects such as residual drowsiness
upon waking. GABA-A receptor modulators, the current
standard of care for insomnia, act by potentiating the ac-
tivity of endogenous neurotransmitters and have a low
threshold of receptor occupancy for in vivo efficacy [25].
This low threshold allows GABA-A receptor modulators
to promote sleep maintenance during the resting period,
but also represents a challenge to terminate their agonist
activity prior to ensuing wake periods to avoid next-day
effects. DORAs provide an alternative mechanism for
the treatment of insomnia by inhibiting the wake-
promoting activity of orexin neuropeptides. As such, a
higher percentage of receptor occupancy is required toFigure 7 OX2R occupancy by suvorexant sufficient for sleep-
promoting efficacy: restricted to 8 h following treatment. The
time courses of plasma levels of suvorexant in humans collected in
Phase 1 clinical trials following administration of suvorexant
(indicated doses) are shown relative to the plasma values (0.33 μM)
calculated to correspond to the exposure required for 65% OX2R
occupancy (dashed line). The gray shaded area represents the
predicted efficacy range based upon this value. occ, occupancy.block the effect of the endogenous peptide ligand in
order to promote sleep. The current studies evaluate
the pharmacokinetic and receptor-binding properties
that contribute to the timing of OX2R receptor occu-
pancy and in vivo efficacy to define the potential of the
DORA mechanism of action to promote sleep mainten-
ance during the resting phase while avoiding next-day
residual effects.
The capacity of orexin receptor antagonists to block
orexin-induced arousal at a given time of day is
dependent upon endogenous orexin neuropeptide levels.
This signal window was defined by evaluating OX-A
levels in two nocturnal and two diurnal species and was
correlated with sleep/wake cycles in which the highest
levels of wakefulness were observed during the active
phase and the lowest levels during the inactive phase. As
predicted, the largest observable sleep-promoting effects
of DORAs in rats were greatest during the active phase
when orexin levels were highest, and effects were dimin-
ished during the inactive phase, consistent with previous
studies of other DORAs [10-12]. Importantly, effects
of DORAs detected during the resting phase were an
augmentation of normal sleep parameters, including fur-
ther attenuation of active wake, promotion of SWS, and
REM sleep that was either unchanged (as seen in the
present studies) or improved [10,11]. Previous analysis
of DORA-22-induced changes in qEEG spectral power
during the inactive phase found only minimal changes in
frequency distribution relative to vehicle treatment, indi-
cating minimal disruption of qEEG patterns during the
resting phase [20]. These results were supported by the
observed effects of DORA-22 on resting-phase qEEG in
rhesus monkeys where gamma and theta activity re-
mained unchanged while delta frequency power was
augmented from the pattern normally seen in vehicle-
treated animals (see Figure 6C). In stark contrast, the ef-
fects of the GABA-A receptor modulators diazepam and
eszopiclone increased high frequency gamma power and
suppressed theta activity in directions that were diamet-
rically opposed to those normally observed during the
resting phase of vehicle-treated animals. These results
are consistent with disrupted sleep-stage-specific qEEG
spectral patterns induced by GABA-A receptor modula-
tors, observed previously in rats [20] and humans [15].
The relatively minimal effects of DORA-22 on both
sleep and qEEG spectral patterns further indicate that
DORAs selectively block orexin-mediated arousal, which
is at its lowest during the normal resting phase.
The etiology of insomnia is not well understood at the
neurotransmitter or neuronal pathway level, and changes
in orexin levels have yet to be demonstrated as a cause
of insomnia. As such, translatable preclinical models for
insomnia have not been developed and the studies
performed in the current work only mimic the normal,
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during the normal inactive phase. However, orexin
levels have been observed to increase with wake-related
motor activity associated with forced swimming in rats
[26], in patients with restless legs syndrome [27], and
are diminished in narcoleptic patients based on exam-
ination of CSF levels derived from lumbar collection
[28]. Persistent and significant reductions in wakeful-
ness have been observed during the resting phase of
insomnia patients in response to suvorexant treatment
[17] and to SB-649868 in a situational model of in-
somnia [15]. These clinical observations suggest that
DORAs are effective in reversing elevated orexin sig-
naling present in insomnia patients.
This work in rats and dogs demonstrates that salient
sleep promotion by DORAs is achieved at plasma levels
necessary for OX2R occupancy to exceed a threshold of
65 to 80% as calculated based on the transgenic rat
model. Sleep promotion in dogs was observed at times
during which suvorexant levels were sufficient for OX2R
occupancies in excess of 65%. In rats, highly significant
active wake attenuation in the 2 h following dosing of
DORA-12 occurred at plasma concentrations corre-
sponding to occupancies of 83% in transgenic animals,
while a trend toward active wake reduction (−9.7%) was
seen at an occupancy of 63% occupancies did not reach
significance in this experiment. While it remains pos-
sible that variation in expression in transgenic animals
expressing the human receptor may have contribute
to slightly different levels of receptor occupancy, the
similar in vitro potency of DORA-12 in humans and rats
(FLIPR Kb = 19 nM and 25 nM, respectively; unpub-
lished observations) indicates that the results in trans-
genic animals were a reasonable facsimile of receptor
binding in genetically unmodified animals. The 65 to
80% occupancy range is consistent with prior studies
measuring OX2R occupancy by orexin antagonists in
specific brain regions. Although efficacy thresholds were
not explicitly defined, Dugovic et al. (2009) did not
observe almorexant efficacy at 78% occupancy, and
appeared to see significant changes at occupancies above
89% [29], while Morairty et al. (2012) saw differential
sleep drop-off when OX2R occupancies diminished from
75 to 63% [30]. Moreover, effective occupancy thresholds
of 65 to 90% for antagonists targeting CNS G protein
coupled receptors such as neuroleptics for D2-like re-
ceptors, have been found previously [31,32]. Compari-
sons between methods, however, should be made with
caution since different approaches utilizing varying assay
incubation times coupled with differing compound off-
rates can influence raw occupancy measurements. Im-
portantly, the pattern of increased OX2R occupancy in
rats alongside dose-dependent attenuation of active wake
with structurally distinct DORAs observed herein and inother published studies [10,12,18] indicates that the
occupancy threshold required for efficacy is a general
property of orexin antagonism and is not compound
dependent. These findings illustrate the importance of
mechanism-dependent differences in receptor occupancy
thresholds in determining the timing of sleep-promoting
efficacy of GABA-A receptor modulators relative to
DORAs. Ideally, insomnia treatments are expected to
normalize the elevated levels of active wake experienced
during disrupted sleep that are characteristic of insomnia
during the resting period (Figure 8A). GABA-A receptor
modulators, including diazepam (a benzodiazepine recep-
tor modulator, BzRM) as well as zolpidem and eszopiclone
(non-BzRMs), exhibit in vivo efficacy at a mean GABA-A
receptor occupancy of 27%. Low levels of receptor engage-
ment are likely due to the receptor activation mechanism
of these compounds leading to amplification of cellular
signaling [25]. This low threshold for efficacy presents a
challenge to GABA-A receptor modulators to restrict their
sleep-promoting effects to the inactive phase. GABA-A re-
ceptor occupancy by diazepam, an anxiolytic BzRM with a
long T1/2, exceeds this occupancy threshold long into the
subsequent active period at sleep-promoting doses. As a
consequence, diazepam exhibits substantial residual effects
(Figure 8B) in terms of both sedation and cognitive mea-
sures (see Figure 6). Non-BzRMs that have a shorter ex-
posure T1/2 more rapidly exceed receptor occupancy
thresholds sufficient for sleep promotion. However, de-
pending on dosage, these non-BzRMs may not maintain
sleep throughout the inactive period, resulting in early
morning awakenings (Figure 8C). Identifying appropriate
dosages that avoid residual effects but maintain resting-
phase efficacy is complicated by the additional non-sleep-
related effects of these compounds. In the current studies,
eszopiclone-induced reductions in active wake were de-
tectable for up to 6 h while qEEG effects were observed al-
most 14 h later and effects on attention for up to 16 h (see
Figure 6).
In contrast, DORAs exhibit in vivo sleep effects at
plasma exposures sufficient for 65% OX2R occupancy,
the higher level of receptor engagement being required
to sufficiently block the activating effect of the orexin
ligand (Figure 8D). This high occupancy threshold re-
quires DORAs to maintain plasma concentrations suffi-
cient to promote sleep maintenance throughout the
normal resting period. At the same time, DORAs are
less likely to exhibit next-day residual somnolence des-
pite being present at measurable plasma levels due to
the high receptor occupancy threshold required for sleep
maintenance. The sleep-promoting effects of falling
levels of the antagonist at the onset of the normal wak-
ing phase are also likely to be countered by accumulat-
ing levels of the endogenous orexin ligand, which might
provide an even faster cessation of DORA-induced
Figure 8 Conceptual model for DORA OX2R occupancy and
efficacy based on pharmacokinetic and receptor-binding
properties. A. Normal and disrupted sleep relative to OX-A levels (solid
black line) during the human inactive period (gray shading). Wake during
disrupted sleep (red dashed line) is punctuated by brief periods of wake
after sleep onset, while normal sleep (blue dashed line) follows orexin
levels. B. Time course of the sleep-promoting efficacy of benzodiazepine-
based GABA-A receptor modulators (BzRMs). Following treatment (gray
arrow), active wake diminishes as GABA-A receptor occupancy (black
dotted line) exceeds that required for sleep efficacy, 27% (horizontal black
dashed line) [25]. Red hatched area, difference from normal active wake
(blue dashed line). Residual effects (R.E.) during the subsequent waking
period as compound levels sufficient for GABA-A receptor occupancy are
exceeded following the normal 8-h resting period. C. Efficacy time course
of non-benzodiazepine GABA-A receptor modulators (non-BzRMs).
GABA-A receptor occupancy (black dotted line) induced by sub-optimal
doses of non-BzRMs are not sufficient to engage these receptors allowing
early morning awakenings (E.M.A.). Yellow hatched area, difference from
normal active wake (blue dashed line). D. DORAs, sufficiently engineered
for optimal pharmacokinetic and receptor-binding kinetics, induce OX2R
occupancies (black dotted line) sufficient to block the wake-promoting
properties of orexin throughout the 8-h resting period and, given the
high level of OX2R occupancy required for sleep-promoting efficacy,
avoid residual effects persisting into the subsequent waking period even
in the presence of moderate levels of compound exposure.
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nists and the relatively close Ki values.
Unlike GABA-A receptor modulators, DORA-22 did
not exhibit next-day residual effects in rhesus monkeys
despite the presence of measurable plasma levels 17 h
after dosing. DORA-22 did not impact next-day sleep,
qEEG, or cognitive measures as compound levels were
insufficient to occupy OX2R above the necessary efficacy
threshold. Diazepam, an anxiolytic with a long T1/2, pro-
moted sleep throughout the normal resting period and
into the subsequent active phase and also impacted
memory and attention. Eszopiclone did not demonstrate
next-day sleep effects or memory impairment; however,
it did significantly impair attention as measured by
SCRT. Although sleep effects did not persist with
eszopiclone, qEEG spectral power changes were evident
up to lights on/performance of DMS tasks. The effect of
cognitive testing on qEEG measures is currently un-
characterized, and the effect of administering a treat-
ment for insomnia in addition to cognitive testing on
qEEG spectral power is even less certain. Direct com-
pound effects may be one possible explanation for the
next-day attention deficits found with eszopiclone, as
measurable concentrations (535 nM) were reported 17 h
after administration. Another possibility is that this at-
tention deficit is a consequence of abnormal sleep occur-
ring during the previous inactive phase. Sleep-stage
disruption, particularly of REM sleep, which is thought
to restore cognitive performance [33,34], may be respon-
sible for potentiating this deficit. Eszopiclone induced
substantial changes in gamma and theta qEEG spectral
power relative to vehicle for the entire resting period – a
result consistent with both suppressed REM sleep and
disrupted sleep-stage-specific EEG spectral activity ob-
served in previous studies [15,20].
Conversely, the lack of qEEG spectral disruption by
DORA-22 during the previous resting phase was associ-
ated with no such cognitive impairment. Currently, it is
unclear whether the lack of cognitive impairment by
DORA-22 is due to the promotion of unperturbed sleep
or a lack of on-drug cognitive effects. Indeed, cognitive
assessment of rhesus monkeys performed within 2 h fol-
lowing treatment indicated no impairment in DMS and
SCRT tasks with DORA-22, but substantial deficits were
induced by diazepam, eszopiclone, and zolpidem at
sleep-promoting doses [24].
Even if DORA levels sufficient to exceed the OX2R ef-
ficacy threshold are present at the onset of wake, emer-
ging preclinical data indicate that these effects are
expected to be benign relative to those induced by
GABA-A receptor modulators. When evaluated acutely
(< 4 h after treatment), DORAs have little or no impact
on locomotor coordination in rats [35], or on memory
or attention in rats and rhesus monkeys [24]. This is in
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substantial deficits when measured acutely [24,35]. While
these differential effects remain to be investigated clinic-
ally, results in preclinical species indicate another funda-
mental difference between blockade of orexin signaling
and GABA-A receptor activation.
The sleep promoting effect of DORAs is the result of
the inhibition of orexin-induced arousal primarily medi-
ated through OX2R. Genetically, loss of this receptor
is associated with narcolepsy in dogs [36] and the
hypersomnolent phenotype of mice lacking OX2R is
similar to that of those lacking both receptors or Hcrt
gene encoding orexin ligands [37,38], while OX1R KOs
reportedly display only a minor, sleep fragmentation
phenotype [39]. Pharmacologically, OX2R selective an-
tagonists induce sleep promoting effects similar to that
of DORAs, while OX1R selective antagonists adminis-
tered alone exhibit only minor, if detectable effects
on vigilance state [29,30]. It has been suggested that
OX1R inhibitory activity of DORAs may counter the
effect of OX2R inhibition by these compounds through a
dopamine-mediated mechanism [29], but further evaluation
using alternative OX1R and OX2R selective antagonists of
different selectivity has questioned this conclusion [30].
Based on these preclinical evaluations of structurally
divergent DORAs, suvorexant exhibits a pharmacoki-
netic profile predicted to be advantageous for the treat-
ment of insomnia. Analysis of the time course of
suvorexant plasma concentrations determined in an
early Phase 1 clinical trial indicates that concentrations
sufficient for efficacy in humans (0.33 μM for 65% OX2R
occupancy based on normalization from the rat trans-
genic model) are restricted to normal sleep periods while
efficacy is maintained for a range of doses. Given their
high OX2R occupancy threshold for efficacy, DORAs
require a plasma concentration sufficient to maintain oc-
cupancy in order to promote sleep throughout the rest-
ing period in humans. For suvorexant, this is achieved
with a plasma concentration T1/2 exceeding 8 h. In early
clinical trials, suvorexant exhibited an apparent terminal
T1/2 of 9 to 13 h [40] – pharmacokinetic timing appro-
priate for sleep maintenance.
Although insomnia is a common disorder, its under-
lying mechanisms are still not fully understood. DORAs
have been rationally designed specifically to promote
sleep by blocking wakefulness and thus alleviate the
symptoms of insomnia while minimizing potential off-
target activity that occurs with widespread signaling via
GABA-A receptor modulators. By using antagonist com-
pounds like suvorexant to block the arousal-promoting
effects of orexin signaling in the brain, the oscillation in
endogenous orexin pathway activation (highest signaling
during active periods and diminished signaling during
normal sleep times) is modified to mimic more closelythe expected physiological state in normal sleep and
wakefulness.
Conclusion
The combination of desirable pharmacokinetic and
receptor-binding properties as well as a high level of
OX2R occupancy necessary to antagonize the wake pro-
moting effects of the endogenous orexin ligand allows
DORAs to alleviate insomnia symptoms during normal
sleep periods while avoiding residual somnolence during
subsequent waking periods. These data support the the-
sis that DORAs such as suvorexant may have pharmaco-
logical and kinetic-binding properties appropriate for the
treatment of insomnia.
Methods
All animal studies were performed in accordance with
The National Research Council’s Guide for the Care and
Use of Laboratory Animals (http://www.nap.edu/catalog.
php?record_id=12910) and were approved by the Merck
Institutional Animal Care and Use Committee. All ef-
forts were made to minimize animal use and suffering.
Detection of orexin-A in cerebrospinal fluid
CSF was collected via cisterna magna puncture similarly
from male and female beagles and rhesus monkeys
(Macaca mulatta) similarly. Propofol (i.v., 2–8 mg/kg, to
effect ) anesthetized dogs were maintained on isofluorane
anesthesia via an endotracheal tube. Using aseptic tech-
nique, a 1.5 inch spinal needle with stylet is introduced
through the skin and subcutaneous tissue and then
through the atlanto-occipital membrane which connects
the first vertebrae with the skull and overlies the cisterna
magna. The stylet is then removed from the needle and
cerebrospinal fluid is allowed to flow into a collection
tube. CSF was collected from conscious male and female
rhesus monkeys (Macaca mulatta) using methods de-
scribed previously [41], and similar to those procedures
employed in dog.
CSF was collected from Male Sprague–Dawley rats
(Taconic Farms, Hudson, NY) under isofluorane anesthesia
(5% with oxygen at 2 L/min in an induction hood, 2%
thereafter) and on a circulating water warming blanket.
Heads were shaved from the posterior portion to the dorsal
thoracic area exposing region just above the cisterna
magna, and placed on stereotaxic apparatus to position the
head of the rat at a 70-80° bend. After identifying the area
by palpation, a 25 g × 5/8” butterfly needle, with 12” of tub-
ing (Terumo Surflo Winged Infusion Set, Terumo Corpor-
ation, Somerset, NJ) is slowly inserted into the cisterna
magna of the rat. A small suction is applied from a syringe
connected to the end of the winged infusion set until fluid
is observed in the tubing. CSF is then collected by expul-
sion into a microfuge tube. CSF was similarly collected
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cept that the procedure is a non-survival surgery in mice,
and animals are rapidly euthanized following CSF recovery.
For mice, a stereotaxic device is fashioned from the styro-
foam 15 mL conical tube holder, and skin and muscle cov-
ering the head and neck area are removed to visualize the
dura mater prior to CSF collection.
Concentrations of OX-A within CSF were quantified by
immunoassay developed using the Meso Scale Discovery
(MSD) electrochemiluminescence detection technology
platform (Gaithersburg, MD, USA). Purified polyclonal im-
munoglobulin G (G-003-36, Phoenix Peptide, Burlingame,
CA, USA), raised in rabbit against OX-A (amino acids
16–33) amide, was used as the capture antibody. Goat
anti-human polyclonal antibody against orexin-A (N-18)
(sc-26491, Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) was used as the primary detection antibody.
Sulfo-Tag-labeled anti-goat antibody, raised in donkey,
was used as the secondary detection antibody and was pro-
vided by MSD (R32AG-5). Assay wash buffer (R61TX-1)
was also sourced from MSD. Blocking buffer was gener-
ated by dissolving membrane blocking agent (RPN-2125,
GE Healthcare, Buckinghamshire, UK) in MSD wash
buffer (1.5 g per 50 mL). Antibody and orexin stand-
ard diluent was made by diluting blocking buffer
three-fold in wash buffer. Standard OX-A (full length
peptide) was sourced from Phoenix Peptide (003–30,
Burlingame, CA, USA).
Plates were incubated overnight with 25 μL of capture
antibody (3.33 μg/mL) and washed three times using
MSD wash buffer (200 μL per well). Plates were then in-
cubated with blocking buffer (150 μL per well) on a Titer
Plate Shaker (Barnstead International, Dubuque, IA,
USA) for 1 h at room temperature. After aspirating
blocking buffer, orexin standards (reconstituted in anti-
body diluent) or samples (25 μL) were added to each
well. The plates were sealed and incubated, shaking for
2 h at room temperature. Following incubation with
standards and samples, plates were washed an additional
three times with 200 μL per well of wash buffer. Next,
25 μL of primary antibody dilution (1 μg per mL) was
added to each well and plates were sealed and incu-
bated while shaking for 1 h at room temperature. Fol-
lowing an additional wash step, 25 μL of secondary
antibody dilution (0.5 μg per mL) was added to each
well, and plates were sealed and incubated, shaking, for
1 h at room temperature. As a final step, 150 μL of read
buffer was added to each well and plates were read
on an MSD sector imager. All measurements were
performed in triplicate.
EEG
The mean time spent in sleep stages was determined in
radio-telemetry-implanted mice, rats, dogs, and rhesusmonkeys as first described by Renger and colleagues [42]
and subsequently by Winrow and colleagues [12,18] with
minor modifications. For baseline studies, recordings
were taken continuously from unperturbed mice, rats,
dogs, and monkeys for 6, 6, 10, or 5 days, respectively,
and the mean time spent in all sleep stages in 30-min in-
tervals were averaged and plotted onto a single 24-h
period (Figure 1). Almorexant is a DORA [43] that was
previously in clinical development for the treatment of
insomnia [10,44]. The clinical development program for
almorexant was terminated in early 2011. For rat studies
in which DORA-22, DORA-12, or almorexant were ad-
ministered, a balanced 3-day cross-over design was
employed in which all animals were treated alternately
with vehicle (20% Vitamin E d-alpha tocopheryl poly-
ethylene glycol 1000 succinate [TPGS], orally [per os,
p.o.]) and compound for 3 consecutive days with a 5-day
intervening washout period, animals being divided ran-
domly into either vehicle- or compound-first groups. In
all cases, mean time in active wake, quiet wake, SWS,
and REM sleep was determined for each 30-min inter-
val for 3 days of each condition and averaged onto a
single 24-h period. Automated sleep-stage data collec-
tion and analysis were performed as described in detail
previously [12]. Statistical differences in mean time
spent in active wake, quiet wake, SWS, and REM sleep
between vehicle- and compound-treated groups at 30-
min time points were determined by a linear mixed-
effects model applied t-test.
EEG responses to diazepam (10 mg/kg, p.o. in 0.5%
methylcellulose); eszopiclone (10 mg/kg, p.o. in 20% Vita-
min E TPGS) and DORA 22 (30 mg/kg, p.o. in 20%
Vitamin E TPGS) were evaluated in rhesus monkeys
implanted with subcutaneous telemetric devices (D70-
EEE; Data Sciences International, Arden Hills MN)
housed in a 12:12 light cycle with lights-off at 16:30
and lights-on at 04:30. Animals were fed on a calorie-
controlled diet of laboratory chow supplemented with
fruit and vegetables. Water was available ad libitum
with the exception of those monkeys trained to perform
cognitive tasks, for which access was restricted for up
to 4 h prior to and during cognitive testing. Treatment
occurred at 14:40 (Zeitgeber time [ZT] 10:10) in a bal-
anced 1-day cross-over design: 1 day of drug or vehicle
followed by 6 days of baseline followed by 1 day of
vehicle or drug. Cognition tasks were scheduled for
next-day evaluation as described below. Sleep/wake
architecture was scored according to vigilance state (ac-
tive wake, quiet wake, delta sleep I, delta sleep II, and
REM sleep) at 30-minute intervals and analyzed as pre-
viously described [24]. Spectral analysis of continuous
EEG was quantified between vehicle and compound
after binning continuous frequencies into canonical fre-
quency bands (reported herein: Delta, 0.5 – 4 Hz;
Gotter et al. BMC Neuroscience 2013, 14:90 Page 14 of 16
http://www.biomedcentral.com/1471-2202/14/90Theta, 4.0 – 7 Hz; Gamma, 35.0 – 100.0 Hz). qEEG
values are spectral power (uV2) log transformed before
analysis and averaged over 30-minute intervals, ex-
pressed as means +/− SEM, and compared with vehicle
using a mixed-model ANOVA at each time point with
random effects for subject and date within subject in
the R statistical computing environment (cran.us.r-
project.org; the R Foundation for Statistical Computing,
Vienna, Austria) using a linear mixed effects model for
significance testing. Significant conditional differences
are indicated as tick marks at the top of the graphs
(short, P ≤ 0.05; medium, P ≤ 0.01; long, P ≤ 0.001) with
gray vertical bars through significantly different data
points.
OX2R occupancy
Occupancy of human OX2R in transgenic rats express-
ing the receptor via the rat enolase promoter was
performed ex vivo in radioligand-binding-displacement
assays essentially as previously described [21] with minor
modifications. To determine the relationship between
OX2R occupancy for a given compound over a full range
of plasma and CSF concentrations, hOX2R-expressing
rats were dosed i.v. with compound. Immediately follow-
ing 30 min of i.v. administration, animals were anesthe-
tized, sacrificed, and CSF, blood, and brain tissue were
harvested and frozen for analysis. Frozen tissue was
weighed and thawed coincident with homogenization.
The homogenate was pelleted at 21,000 × g for 1 min
and the pellet was resuspended. A binding assay was run
with brain tissue and radio ligand at ~ 10 × Kd and
filtered at 12 min (in the linear association phase). Non-
specific binding was determined by the addition of
1000-fold excess unlabeled ligand. Experimental (dosed)-
specific binding was compared with control (vehicle-
dosed) binding ([specific total counts minus specific
experimental counts]/specific total counts × 100 =
percent occupancy). Raw occupancy values determined
in this manner over a range of plasma and CSF values
were then used to construct a normalized curve where
the theoretical maximum occupancy value was defined
as 100% and occupancies relative to plasma or CSF
values were fit to a one-sided binding (hyperbola) curve
(GraphPad Prism, San Diego, CA, USA). Plasma values
determined from PSG experiments in satellite animals
were then used to determine corresponding occu-
pancy values from best fit curves for a given com-
pound at Cmax. In separate experiments, plasma, CSF,
and brain tissue was collected at time points follow-
ing dosing to directly measure compound levels and
corresponding OX2R occupancies at these times.
Resulting occupancy relative to measured plasma
levels of compound was fit to a normalized binding
curve as described previously [21].OX2R occupancy in dogs and humans was calculated
based on the plasma/occupancy relation determined in
rats and corrected for the free fraction of suvorexant in
each species. In dogs, suvorexant plasma levels deter-
mined in satellite animals coincident with PSG studies
reported by Winrow and colleagues [12] were used to
calculate OX2R occupancy levels based on standard
curves of OX2R occupancy in rats versus the free frac-
tion of plasma suvorexant levels. Human free plasma
levels of suvorexant sufficient for 80% OX2R occupancy
were calculated based on extensive rat data and normal-
ized for free fraction (rat: 1.4%; human: 1%). The plasma
level of suvorexant calculated to correspond to 80%
OX2R occupancy in humans is 0.71 μM (free + bound)
[17]. Human plasma levels of suvorexant collected in
Phase 1 (10, 20, 50, and 76 mg doses) and Phase 2/3
(steady state, 40 mg) clinical trials were plotted against
the suvorexant plasma value calculated to correspond to
the exposure required for the OX2R occupancy deter-
mined from standard OX2R occupancy versus free frac-
tion exposure curves of preclinical species.Monkey Delayed Match to Sample (DMS) task
All cognition testing occurred in the animal’s home cage
equipped with a touchscreen. Each DMS trial was initi-
ated with a single ‘sample’ image (150 × 200 pixels: 1.8
inches × 2.3 inches) in one of eight colors presented at
the center of a touchscreen. Evaluation began when the
monkey touched the sample image, at which point the
screen became blank for a retention period. Following
the retention period, four choice images (150 × 200
pixels) were presented, one in each corner of the screen.
One of the four choice images matched the color of the
sample image, whereas the three remaining ‘distractor’
images were drawn from the pool of remaining colors.
A reinforcer was provided when the monkey touched
the choice image that matched the color of the sample
image. Incorrect choices were not reinforced and re-
sulted in a 5 s timeout. On completion of the trial, an
inter-trial interval of 5 s was presented prior to the next
trial, and failure to respond to the samples or choice im-
ages within 30 s resulted in the screen turning blank for
a 5 s timeout prior to initiating another trial. Test ses-
sions comprised 96 trials or lasted for up to 45 min.
Three discrete retention intervals were titrated for each
subject’s baseline performance in the absence of com-
pound to yield performances of approximately 80–100%,
55–65%, and 35–45% of responses being correct at
short, medium, and long retention intervals, and ranged
from 0.25–0.5 s, 2.5–14 s, and 9–39 s, respectively. Re-
sponse latencies to sample and choice images were also
recorded. Values reported reflect the proportion of
correct responses collapsed over all retention intervals.
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measures ANOVA.Monkey Serial Choice Reaction Time (SCRT) task
Each SCRT trial was initiated with the appearance of 10
blue square ‘target’ images evenly distributed at 3-inch in-
tervals around the perimeter of a touchscreen presented
together with a centrally located circular ‘centering’ image
(1.4 inch diameter circle). The task began with the mon-
key touching the centering image, which then turned gray.
The monkey was then required to touch the centering
image continuously throughout a variable pre-cue interval
of 0.25-7.5 s. On completion of the pre-cue interval, one
of the blue target images was cued by turning red for one
of four cue durations before turning back to blue. To ob-
tain a reward, the monkey was required to touch the tar-
get image that had been ‘cued’ red within a 5 s limited
hold period. Inaccurate choices were not reinforced and
resulted in a 3 s timeout. On completion of the trial, an
inter-trial interval of 2 s was initiated prior to the next
trial. A failure to respond to the centering image within
60 s resulted in the screen becoming blank for a 2 s time-
out prior to the start of the next trial. If the monkey initi-
ated a trial but removed its hand from the touchscreen
prior to the appearance of the cue, the trial was termi-
nated and the screen was blanked during a 2 s inter-trial
interval. Sessions were terminated after 20 min. Cue loca-
tion and duration were pseudo-randomly assigned. Cue
duration and the target size were titrated for each subject
on the basis of performance during previous baseline ses-
sions to yield a performance of 60–80% correct responses
for the trials of the shortest cue duration. The briefest cue
duration varied from 0.04–0.1 s and the cues varied in size
from 0.2–0.7 inches, although each cue had the same
touch-sensitive area of 1.75 inches. Values reported in the
current study reflect the proportion of correct responses
to targets after cues of the shortest duration only.
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